Cart
0
Get 20% Free Customization In This Report
By this report from - $4747

IVIG Market (Intravenous Immunoglobulin Market) by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome), Type (IgG, IgA, IgM, IgE, and IgD) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

LI 16325
Pages: 131
Dec 2016 | 4184 Views
face gplus_n
Author's : Onkar Sumant
Tables: 37
Charts: 29
twit_n pr_n

IVIG Market Overview:

IVIG market (Intravenous Immunoglobulin Market) was valued at $7,861 million, and is expected to reach $12,632 million by 2022, supported by a CAGR of 7.1%. Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies. 

IVIG market is driven by the increase in prevalence of chronic inflammatory demyelinating polyneuropathy and hypogammaglobulinemia, and rise in use of immunoglobulins to treat GuillainBarre syndrome, inflammatory myopathies, specific antibody deficiency, and others. Further, the increase in approval of intravenous immunoglobulin (IVIG) drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the sales of immunoglobulin.

Increase in geriatric population and hemophilic patients, improved IVIG production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield) are the other key factors that contribute to the IVIG market growth. In addition, the market is restrained by the stringent government regulations, high cost of therapy, and high risk of side effects associated with the use of IVIG.

North America currently dominates the IVIG market, in terms of revenue, followed by Asia-Pacific owing to high adoption of its treatments, high plasma collection, and large patient population. LAMEA is expected to grow at a high CAGR of 10% owing to the rise in preference of IVIG therapies and growth in awareness about immunodeficiency diseases in underdeveloped regions.

Key players operating in the IVIG market are Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare.

Market Definition And Scope:

IVIGs are antibodies that are used in the treatment of patients suffering from antibody deficiencies. Currently, IVIG is used for several FDA- and European Medical Agency (EMA)-approved indications and several off-label indications; therefore, the report covers revenue generated from all these indications. IVIG therapy is used for indications such as hypogammaglobulinemia, immunodeficiency, CIDP, myasthenia gravis (MG), multifocal motor neuropathy (MMN), ITP, inflammatory myopathies, specific antibody deficiency (SAD), GBS, and others. Other applications include inflammatory myopathies and other off-label indications. The application market segment is deduced with the help of IVIG adoption pattern for each indication in different economies along with the incidence rate of these indications.

However, it does not include revenue generated from the SCIG consumption. The report does not consider the IVIGs used for research in academic institutes, and services provided by hospitals and clinics.

Top Investment Pockets:

Hypogammaglobulinemia, CIDP, and PID are the most lucrative application segments of the global IVIG market, which collectively accounted for ~50% of the overall market share in 2015. Emergence of potentially advanced technologies, such as recombinant biotechnology, along with the increase in acceptance of IVIG therapies, significantly impacts the IVIG market growth. Despite the high cost associated with IVIG therapy, hypogammaglobulinemia, CIDP, and immunodeficiency diseases remained the highest revenue-generating segments. The global IVIG market for hypogammaglobulinemia expected to grow with a CAGR of 6%. .

IgG replacement therapy is the most preferred treatment option for most immunodeficiency syndromes, namely X-linked, severe combined immunodeficiency, hyper-IgM, adenosine deaminase deficiency, common variable immunodeficiency (CVID), and WiskottAldrich syndrome. Key players such as CSL Ltd., Baxter International Inc., Grifols S.A., Octapharma Inc., and others focus on the development of IVIG therapies to treat various primary immunodeficiency diseases (PIDs). In accordance to the CIDP, IVIG treatment resulted in effective treatment for patients with a CIDP. Approximately, 40% of a patient’s CIDP treated with IVIG needed intermittent IVIG infusions to maintain improved clinical conditions, and it is further expected to be effective throughout the treatment. The global IVIG market for CIDP was valued at $1,629 million in 2015 and is expected to reach $2,452 million by 2022, growing at a CAGR of 6%.

IVIG Market, By Application:

An IVIG preparation has inflammatory and immunomodulatory properties, which expand its traditional use to treat patients with primary immunodeficiency. It is successfully used to treat autoimmune and inflammatory conditions. IVIG preparations along with immunosuppressive agents or monoclonal antibodies are being focused on to increase the use of IVIG. For example, recent studies suggest that IVIG and rituximab (an anti-CD20 monoclonal antibody) combination therapy may be effective to treat autoimmune muco-cutaneous blistering diseases.

Regional and Country Overview:

North America and Asia-Pacific are the most lucrative regional market segments. The market growth of these segments is driven by the large patient population, favorable government policies, increase in purchasing power of the patient population in Asia-Pacific, and awareness about the immunodeficiency disease and other rare autoimmune disorders. U.S., Canada, and China are largest IVIG producers in the global IVIG market. The LAMEA IVIG market, however, is expected to the fastest growing region, growing at a CAGR of 10%. Factors such as increase in use of IVIG for off-label indications and rise in government initiative such as evaluation and development of orphan drugs to provide incentives for sponsors to develop products for rare disease are expected to fuel the growth of the IVIG market in the near future.
In Europe, the French IVIG market was valued at $299 million in 2015, and is expected to reach $474 million by 2022, with a CAGR of 6%.

Key Benefits For Stakeholders:

  • The study provides an in-depth analysis of the global IVIG market to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth is provided.
  • Projections are made by analyzing the current trends and future potential from 2014 to 2022, in terms of volume and value, that help identify the prevailing opportunities.
  • The report covers in-depth analysis of all geographic regions. Government regulations regarding IVIG production and purification are discussed in detail.
  • Competitive intelligence (of leading manufacturers) interprets the competitive scenario across various geographies.

IVIG Market Key Segments

By Application 

  • Hypogammaglobulinemia 
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain‐Barre syndrome 
  • Others

By Type

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Austria
    • Russia
    • Others
  • Asia-Pacific
    • Australia
    • China
    • Japan
    • India
    • Others
  • LAMEA
    • Latin America
    • Africa 
    • Middle East

The key players that operate in the IVIG industry include Grifols S.A., CSL Behring Ltd., Baxter International Inc., Biotest AG, BDI Pharma Inc., China Biologic Products Inc., Kedrion Biopharma Inc., Octapharma AG., and LFB Group. 

 

Chapter: 1. INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS:
1.3. KEY MARKET SEGMENTS:
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst tools and models

Chapter: 2. EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS

3.5.1. Top Factors Impacting global IVIG market
3.5.2. Top Investment PocketsGlobal IVIG Market

3.6. PORTERS FIVE FORCES ANALYSIS

3.6.1. Bargaining power of buyers (Low)
3.6.2. Bargaining power of suppliers (Low)
3.6.3. Threat of new entrants (low)
3.6.4. Threat of substitutes (low)
3.6.5. Intense competitive rivalry (moderate)

3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support Activities

3.8. MARKET SHARE ANALYSIS (2014)
3.9. PRODUCT SCENARIO IN IVIG MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. IVIG regulations in United States and Europe
3.10.2. Reimbursements Scenario

3.11. INDICATIONS FOR IVIG

3.11.1. USFDA Indications

3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.15. MARKET DYNAMICS

3.15.1. Drivers
3.15.2. Restraints
3.15.3. Opportunities

Chapter: 4. IVIG MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

 

Chapter: 5. IVIG MARKET BY PRODUCT TYPES

5.1. IGG

5.1.1. Key Market Trends
5.1.2. Clinical Interpretations

5.2. IGA

5.2.1. Key Market Trends
5.2.2. Clinical interpretation

5.3. IGM

5.3.1. Key Market Trends
5.3.2. Clinical Interpretation

5.4. IGE

5.4.1. Key Market Trends
5.4.2. Clinical Interpretation

5.5. IMMUNOGLOBULIN D (IGD)

5.5.1. Key Market Trends

Chapter: 6. IVIG MARKET, BY GEOGRAPHY

 

6.1. Market size and forecast
6.2. NORTH AMERICA

6.2.1. U.S.

6.2.1.1. U.S. Market size and forecast

6.2.2. Canada

6.2.2.1. Market size and forecast

6.2.3. Mexico

6.2.3.1. Market Size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Market size and forecast
6.3.3. U.K.

6.3.3.1. Market size and forecast

6.3.4. France

6.3.4.1. Market size and forecast

6.3.5. Germany

6.3.5.1. Market size and forecast

6.3.6. Italy

6.3.6.1. Market size and forecast

6.3.7. Austria

6.3.7.1. Market size and forecast

6.3.8. Russia

6.3.8.1. Market size and forecast

6.3.9. Other countries

6.3.9.1. Market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Market size and forecast
6.4.3. Australia

6.4.3.1. Market size and forecast

6.4.4. China

6.4.4.1. Market size and forecast

6.4.5. Japan

6.4.5.1. Market size and forecast

6.4.6. India

6.4.6.1. Market size and forecast

6.4.7. Others

6.4.7.1. Market size and forecast

6.5. LAMEA

6.5.1. Key Market Trends
6.5.2. Market size and forecast
6.5.3. Latin America

6.5.3.1. Market size and forecast

6.5.4. Africa

6.5.4.1. Market size and forecast

6.5.5. Middle East

6.5.5.1. Market size and forecast

Chapter: 7. COMPANY PROFILES

7.1. BIOTEST AG

7.1.1. Company Overview
7.1.2. Biotest AG: Company Snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key Strategic Moves & Developments

7.2. OCTAPHARMA AG

7.2.1. Company Overview
7.2.2. Octapharma AG: Company Snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key Strategic Moves & Developments

7.3. BAXTER INTERNATIONAL INC.

7.3.1. Company Overview
7.3.2. Baxter International, Inc.: Company Snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key Strategic Moves & Developments

7.4. LFB BIOTECHNOLOGIES

7.4.1. Company Overview
7.4.2. LFB Biotechnologies: Company Snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key Strategic Moves & Developments

7.5. CHINA BIOLOGICS PRODUCTS INC.

7.5.1. Company overview
7.5.2. China Biologic Products Inc. Snapshot
7.5.3. Operating business segment overview
7.5.4. Financial performance
7.5.5. Key Strategic Moves & Developments

7.6. GRIFOLS S.A.

7.6.1. Company overview
7.6.2. Grifols S.A Snapshot
7.6.3. Operating Business Segment Overview
7.6.4. Financial performance
7.6.5. Strategic moves and developments

7.7. KEDRION BIOPHARMA

7.7.1. Company overview
7.7.2. Kedrion Biopharma. Snapshot
7.7.3. Operating business segment overview
7.7.4. Financial performance
7.7.5. Strategic moves and developments

7.8. CSL BEHRING

7.8.1. Company overview
7.8.2. CSL Behring Snapshot
7.8.3. Operating business segment overview
7.8.4. Financial performance
7.8.5. Strategic moves and developments

7.9. BDI PHARMA INC.

7.9.1. Company overview
7.9.2. BDI pharma Inc. Snapshot
7.9.3. Operating business segment overview
7.9.4. Strategic moves and developments

7.10. BAYER HEALTHCARE

7.10.1. Company overview
7.10.2. Business performance
7.10.3. Strategic moves and developments

List of Tables

TABLE 1. IVIG PRODUCTS COMMERCIALIZED IN MARKET
TABLE 2. USFDA INDICATIONS FOR IVIG
TABLE 3. EMA APPROVED INDICATIONS FOR IVIG
TABLE 4. IGG SUBCLASS
TABLE 5. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 6. DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
TABLE 7. CLINICAL TRIALS FOR IVIG (2011-2014)
TABLE 8. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022,($MILLION)
TABLE 9. GLOBAL IVIG MARKET, BY APPLICATION, 2014-2022, (TON)
TABLE 10. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 11. HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 12. CIDP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 13. PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
TABLE 14. IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 15. MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 16. MMN IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 17. ITP TREATMENT OPTIONS
TABLE 18. ITP IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 19. INFLAMMATORY MYOPATHIES IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 20. SAD IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 21. GBS IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 22. OTHER IVIG APPLICATION MARKET ($MILLION & TON), 2014-2022
TABLE 23. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, ($MILLION)
TABLE 24. GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2022, (TON)
TABLE 25. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 26. NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 27. U.S. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 28. CANADA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 29. MEXICO IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 30. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 31. EUROPE IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 32. U.K. IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 33. FRANCE IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 34. GERMANY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 35. ITALY IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 36. AUSTRIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 37. RUSSIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 38. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 39. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 40. ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 41. AUSTRALIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 42. CHINA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 43. JAPAN IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 44. INDIA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 45. OTHER IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 46. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, ($ MILLION)
TABLE 47. LAMEA IVIG MARKET, BY COUNTRY, 2014-2022, (TON)
TABLE 48. LATIN AMERICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 49. AFRICA IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 50. MIDDLE EAST IVIG MARKET ($MILLION & TON), 2014-2022
TABLE 51. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 52. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 53. CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
TABLE 54. CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
TABLE 55. GRIFOLS S.A SNAPSHOT
TABLE 56. GRIFOLS S.A OPERATING SEGEMENTS
TABLE 57. KEDRION INC. SNAPSHOT
TABLE 58. KEDRION BIOPHARMA OPERATING SEGMENTS
TABLE 59. CSL BEHRING SNAPSHOT
TABLE 60. CSL BEHRING OPERATING SEGMENTS
TABLE 61. BDI PHARMA INC SNAPSHOT
TABLE 62. BDIPHARMA OPERATING SEGMENTS
TABLE 63. BAYER HEALTHCARE COMPANY SNAPSHOT

List of Figures

FIGURE 1. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
FIGURE 2. TOP FACTORS IMPACTING GLOBAL IVIG MARKET (20152021)
FIGURE 3. TOP INVESTMENT POCKETSGLOBAL IVIG MARKET
FIGURE 4. PORTERS FIVE FORCES ANALYSIS
FIGURE 5. VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET
FIGURE 6. MARKET SHARE ANALYSISGLOBAL IVIG MARKET 2014
FIGURE 7. BIOTEST AG: REVENUE, 2013-2015, ($MILLION)
FIGURE 8. BIOTEST AG: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 9. BIOTEST AG: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 10. OCTAPHARMA AG:REVENUE, 2013-2015, ($MILLION)
FIGURE 11. BAXTER INTERNATIONAL, INC.:REVENUE, 2013-2015, ($MILLION)
FIGURE 12. BAXTER INTERNATIONAL, INC.:REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIGURE 13. BAXTER INTERNATIONAL, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 14. LFB BIOTECHNOLOGIES:REVENUE, 2013-2015, ($MILLION)
FIGURE 15. LFB BIOTECHNOLOGIES: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIGURE 16. LFB BIOTECHNOLOGIES: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 17. CHINA BIOLOGIC PRODUCTS INC:REVENUE, 2013-2015, ($MILLION)
FIGURE 18. CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE, BY SEGMENTS, (2015)
FIGURE 19. GRIFOLS S.A:REVENUE, 2013-2015, ($MILLION)
FIGURE 20. FINANCIAL OF GRIFOLS S.A, BY GEOGRAPHY, (2015)
FIGURE 21. FINANCIAL GRIFOLS S.A., BY PRODUCT GROUPS, (2015)
FIGURE 22. KEDRION BIOPHARMA :REVENUE, 2013-2015, ($MILLION)
FIGURE 23. FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2015)
FIGURE 24. CSL BEHRING:REVENUE, 2013-2015, ($MILLION)
FIGURE 25. CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
FIGURE 26. CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
FIGURE 27. FINANCIAL REVENUE OF BAYER HEALTHCARE 2013-2015
FIGURE 28. FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2015
FIGURE 29. FINANCIALS OF BAYER HEALTHCARE, BY REGIONS, 2015

 

 

Intravenous immunoglobulin (IVIG) is used in the treatment of deficiency disorders such as hypogammaglobulinemia, Kawasaki disease, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Globally, the rise in immunoglobulin deficiency and the associated disorders drive the use of IVIG in clinical settings. GAMUNEX-C, Flebogamma DIF 5% & 10%, Gammaplex, and Kiovig are the key regulated products approved for use in therapy settings. There are several products that are available in market as “off-label” products, including Gammagard Liquid intravenous, Gammagard S/D intravenous, and Bivigam intravenous. 

Recently, a paradigm shift has been observed in the development of sub-cutaneous immunoglobulin therapy, which limits the focus on development of intravenous immunoglobulin-based products. Sub-cutaneous immunoglobulin formulations offer additional advantageous for patients in terms of ease of administration resulting in their increasing use in home settings. The IVIG market is an oligopolistic market, dominated by Grifols, CSL Behring, Baxter International, and Octapharma. Further, these companies have a strong hold on blood fractionation industry, and hence play a key role in determining the cost of blood product commodities such as albumin, fibrinogen, and other plasma entities.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 

Get More Information About This Report

For any queries about purchasing this report, Please fill the form below:

Please input the above text in the input box or click refresh

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Published in May 2017

Blood Market

Download Sample
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts